Results 101 to 110 of about 11,087,757 (202)

Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease

, 2015
Charles Andy Schuetz,1 Siew Hwa Ong,2 Matthias Blüher3 1Evidera Inc., Bethesda, MD, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Department of Medicine, University of Leipzig, Leipzig, Germany Introduction: Dipeptidyl peptidase-4 (DPP-4 ...
Ong SH, Blüher M, Schuetz CA
core  

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.

, 2008
Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1 ...
Bo Ahrén, Ahrén, Bo
core  

DPP-4 Inhibitors

Diabetes Care, 2011
openaire   +2 more sources

Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. [PDF]

J Diabetes Investig
Kubota-Okamoto S, Kubota S, Tsuchida H, Liu Y, Banno S, Imaizumi T, Fujisawa T, Takahashi Y, Kato T, Horikawa Y, Iizuka K, Murakami T, Fujiwara Y, Kuwata H, Yamazaki Y, Seino Y, Tsunekawa S, Yabe D.   +17 more
europepmc   +1 more source

Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients? [PDF]

North Clin Istanb, 2022
Erol RS, Sen EC, Ozturk FY, Sarac Z, Kokoglu GL, Canat MM, Yildiz D, Aytekin YE, Sevgi DY, Altuntas Y.   +9 more
europepmc   +1 more source

Gingival-Dominant Presentation of DPP-4 Inhibitor-Associated Bullous Pemphigoid: A Case Report. [PDF]

Cureus
Fujii Y, Kataoka T, Togashi C, Ishikawa M, Kawase-Koga Y.   +4 more
europepmc   +1 more source

Comparison of DPP-4 Inhibitors

The Journal of Korean Diabetes, 2013
Nam Hoon Kim, Sin Gon Kim
openaire   +1 more source

Preclinical pharmacological profiles of cofrogliptin, a novel and bi-weekly DPP-4 inhibitor. [PDF]

Front Pharmacol
Gou X, Dou C, Tang P, Zheng X, Zhang C, Wang J, Meng Q, Wang J.   +7 more
europepmc   +1 more source

Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes. [PDF]

J Manag Care Spec Pharm, 2021
Kheloussi S, Johns A, Parente V, McLay W, Gionfriddo MR.   +4 more
europepmc   +1 more source

Successful management of DPP-4 inhibitor-induced bullous pemphigoid with Stapokibart injection in an elderly diabetic patient: a case report. [PDF]

Front Med (Lausanne)
Yu M, Tian S, Meng F.
europepmc   +1 more source